From the Guidelines
Elevated Factor VIII levels can occur due to various reasons including acute inflammation, chronic inflammation, infections, pregnancy, stress, exercise, liver disease, cancer, and genetic factors, and are associated with an increased risk of venous thromboembolism. Factor VIII is an acute phase reactant, meaning its levels rise in response to inflammation or tissue damage. Conditions like rheumatoid arthritis, inflammatory bowel disease, and infections can trigger this response 1. Pregnancy naturally increases Factor VIII as part of the body's preparation for childbirth. Stress and intense exercise temporarily elevate levels through physiological stress responses. Liver disease affects Factor VIII production since the liver synthesizes many clotting factors. Some cancers, particularly lymphomas and solid tumors, can increase Factor VIII levels 2. Genetic variations can also lead to persistently high levels, which may increase thrombosis risk. Certain medications like oral contraceptives and hormone replacement therapy can raise Factor VIII.
Some key points to consider when evaluating elevated Factor VIII levels include:
- The patient's medical history, including any history of thrombotic events or bleeding disorders
- The presence of any underlying conditions that may be contributing to the elevated Factor VIII levels, such as inflammation or cancer
- The use of any medications that may be affecting Factor VIII levels
- The patient's lifestyle factors, such as smoking or obesity, which may increase the risk of thrombosis
It is essential to identify and address the underlying cause of elevated Factor VIII levels, as they are associated with an increased risk of venous thromboembolism 3. A thorough evaluation and management plan should be developed to reduce the risk of thrombotic events and improve patient outcomes.
From the Research
Elevated Factor 8 Reasons
Elevated factor VIII levels have been associated with an increased risk of venous thromboembolism (VTE) in cancer patients, as shown in the Cancer and Thrombosis Study 4. The study found that patients with elevated FVIII levels had a cumulative probability of VTE of 14% after 6 months, compared to 4% in those with normal levels.
- The association between FVIII and VTE risk was strongest in younger patients, with a 2-fold increase in VTE risk per 20% increase in factor VIII levels 4.
- High factor VIII levels are also a risk factor for arterial thrombosis, although the impact is greater on venous than on arterial thrombosis 5.
- The measurement of factor VIII levels is not currently recommended as part of routine thrombophilia screening due to a lack of international consensus on laboratory testing methods 5.
Relationship to Anticoagulation Therapy
Elevated factor VIII levels can affect the management of anticoagulation therapy in patients with cancer-associated thrombosis.
- Low-molecular-weight heparin (LMWH) is recommended as a first-line treatment for patients with VTE and active cancer 6.
- Direct oral anticoagulants (DOACs) are also being considered for use in cancer patients, although their efficacy and safety in this population are still being studied 7, 6.
- The choice of anticoagulant therapy should be individualized based on the patient's risk factors, including their factor VIII levels, and the potential benefits and risks of each treatment option.
Clinical Implications
The association between elevated factor VIII levels and thrombosis risk has important clinical implications for the management of patients with cancer-associated thrombosis.
- Patients with elevated factor VIII levels should be closely monitored for signs and symptoms of thrombosis, and anticoagulation therapy should be adjusted accordingly 4.
- The use of LMWH or DOACs should be considered in patients with elevated factor VIII levels, although the choice of therapy will depend on individual patient factors 7, 6.